Financial Performance - The company's operating revenue for the first half of 2023 was ¥5,868,718,925.46, a decrease of 12.40% compared to ¥6,699,663,435.01 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥387,144,741.66, down 30.86% from ¥559,915,559.98 in the previous year[22]. - The net cash flow from operating activities decreased by 53.99%, amounting to ¥249,048,807.80 compared to ¥541,238,737.12 in the same period last year[22]. - Basic earnings per share were ¥0.1955, reflecting a decline of 30.87% from ¥0.2828 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥377,173,488.57, a decrease of 32.37% from ¥557,705,491.22 in the same period last year[22]. - The company's total revenue for the reporting period was ¥5,868,718,925.46, a decrease of 12.40% compared to ¥6,699,663,435.01 in the same period last year[68]. - The revenue from the pharmaceutical industry increased by 4.82% to ¥1,568,016,956.29, accounting for 26.72% of total revenue[69]. - Revenue from the agrochemical new materials industry decreased by 29.73% to ¥3,320,431,062.53, representing 56.58% of total revenue[69]. - The company reported a net profit margin of 18% for the first half of 2023, an increase from 15% in the same period last year[120]. Assets and Liabilities - Total assets at the end of the reporting period were ¥30,427,589,050.92, representing a 1.33% increase from ¥30,024,403,300.33 at the end of the previous year[22]. - The total restricted assets at the end of the reporting period amounted to CNY 6,864,165,687.51, primarily due to pledged loans and guarantees[79]. - The total amount of external guarantees approved during the reporting period was 38 million yuan, with actual guarantees amounting to 34.5 million yuan[172]. - The total guarantee amount approved for subsidiaries during the reporting period was 565,925, with an actual guarantee amount of 384,477.06[175]. Research and Development - The company invested ¥222,535,452.13 in R&D, which is a 20.11% increase from ¥185,278,131.46 in the previous year[68]. - The company has developed 2 new class drugs and over 20 first research drugs, with 180 patents granted, including 3 international patents[52]. - The company has established a comprehensive drug development system covering raw materials, formulations, pharmacology, and clinical trials, with a focus on dermatological preparations[53]. - The company is actively promoting smart and green manufacturing, which has significantly improved product quality and production efficiency[46]. Market Expansion and Strategy - The company is expanding its overseas raw material drug market while consolidating its leading position in the prescription market domestically[31]. - The company is actively exploring the retail market to increase its market share outside of the prescription market, aiming to enhance product diversity and meet market demands[91]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[120]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's R&D capabilities and add 150 million in annual revenue[120]. Environmental Compliance and Sustainability - The company is committed to environmental protection and safety management, implementing a comprehensive internal management system to address potential risks in production and operations[93]. - The company has established an environmental protection management department to ensure compliance with increasingly stringent environmental regulations in the chemical industry[96]. - The company has implemented measures to ensure that all emissions are within the regulatory limits, demonstrating commitment to environmental standards[114]. - The company has invested in complete environmental protection facilities to ensure compliance with legal requirements for pollutant disposal[141]. Operational Efficiency - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by the end of 2023[120]. - The company has successfully reduced operational costs by 5% through efficiency improvements in the supply chain[177]. - The company is focusing on improving hotel quality and service to increase revenue while controlling operational costs in a competitive market[97]. Corporate Governance - The company reported a focus on customer-driven strategies, integrating production management, supply chain operations, and market sales to respond to client needs effectively[45]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[102]. - The annual shareholders' meeting had a participation rate of 26.97% and was held on May 17, 2023[101]. Community Engagement - The company provided financial assistance of 920,000 yuan for poverty alleviation and rural revitalization, benefiting over 7,650 people in Jiangsu, Jiangxi, and Shandong provinces[152].

单位：万元 非经营性资金 占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核 算的会计科 目 2023 年期初 占用资金余 额 2023 年 1-6 月占用累计 发生金额 （不含利 息） 2023 年 1- 6 月占用资 金的利息 （如有） 2023 年 1- 6 月偿还 累计发生 金额 2023 年 6 月 30 日占 用资金余额 占用形成 原因 占用性质 控股股东、实 际控制人及其 附属企业 小计 - - - 前控股股东、 实际控制人及 其附属企业 小计 - - - 其他关联方及 附属企业 小计 总计 - - - 华邦生命健康股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 华邦生命健康股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 1/3 | | | | | | 2023 年 1-6 | | 2023 年 1- | 2023 年 | 1- | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其它关联资金 | ...

二、关联方资金占用情况 华邦生命健康股份有限公司独立董事 关于控股股东及其他关联方占用公司资金及对外担保情况 的专项说明及独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》、《深圳证券交易所股票上市规则》（以下简称《股票上市规则》） 相关法律、法规和《公司章程》相关规定，作为华邦生命健康股份有限公司（以 下简称"公司"）的独立董事，本着实事求是的原则，对公司对外担保情况和 2023 年半年度的关联方资金占用情况进行认真细致的核查，现发表如下专项说 明和独立意见： 一、对外担保情况 1、公司为全资及控股子公司担保情况 截止 2023 年 6 月 30 日，公司及控股子公司之间、子公司与子公司之间的实 际担保金额为 493,865.25 万元，占公司最近一期经审计的合并报表总资产的 16.45%，占公司最近一期经审计的合并报表净资产的 29.84%，占公司最近一期 经审计的合并报表归属于上市公司的净资产的 48.46%。 2、对外担保 公司分别于 2020 年 4 月 13 日、2020 年 5 月 15 日召开了第七届董事会第十 四次会议及 2019 年年度股东大会 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20230505 投资者关 系活动类 别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 参与单位 名称及人 员姓名 通过全景网"投资者关系互动平台"（网址：http://ir.p5w.net） 参与公司 2022 年度&2023 年一季报业绩说明会的投资者 时间 2023 年 5 月 5 日 (周五) 下午 15:00-17:00 地点 全景网"投资者关系互动平台"（网址：http://ir.p5w.net） 上市公司 接待人员 姓名 董事、总经理：张海安 董事、董事会秘书：彭云辉 独立董事：黎明 财务总监：王剑 投资者关 系活动主 要内容介 绍 1、在颖泰生物利润大幅下降的情况下，公司一季报利润能小幅 上涨，有点意外，请领导介绍一下一季报的利润来源，构成情况， 谢谢。 投资者您好，公司 2023 年一季报归母净利润与去年同期相比实 现增幅 5.1%，虽然颖泰生物本期利润出现大幅下降，但公司对颖泰 生物的持股比例 47.07%所受影响有限，同时，公司医药板块经营状 况良好，持 ...

Financial Performance - The company's operating revenue for the current period is CNY 2,975,546,798.68, a decrease of 12.46% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company is CNY 177,137,767.78, an increase of 5.05% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 168,985,255.18, reflecting a 4.78% increase compared to the previous year[9]. - The net profit for the first quarter was 294,842,240.23 CNY, a decrease from 319,793,662.55 CNY in the previous year, representing a decline of approximately 7.3%[44]. - The total profit amounted to 366,979,165.37 CNY, down from 478,322,104.63 CNY, indicating a decrease of about 23.2% year-over-year[44]. - The company's operating profit was 373,052,903.14 CNY, compared to 479,840,467.75 CNY in the same period last year, reflecting a decline of approximately 22.2%[44]. - The basic earnings per share increased to 0.0895 CNY from 0.0852 CNY, showing a growth of about 2.7%[44]. Cash Flow - The net cash flow from operating activities shows a significant decline of 108.00%, with a current value of CNY -12,813,669.92[9]. - Net cash flow from operating activities turned negative at -¥12,813,669.92 compared to ¥160,139,339.82, a decline of 108.00% attributed to decreased sales volume[34]. - Cash inflow from investment activities totaled ¥2,619,725,609.42, an increase from ¥2,055,850,849.49 in the previous period[25]. - Cash outflow for investment activities was ¥2,667,219,986.51, significantly higher than ¥2,029,269,337.09 in the previous period[25]. - The company reported a net cash flow from financing activities of ¥271,341,170.39, compared to ¥41,768,134.81 in the previous period[25]. - The net cash outflow from financing activities was -7,096,160.62 CNY, an improvement compared to -143,352,411.67 CNY in the previous year[46]. - The total cash outflow from financing activities was 1,695,183,231.01 CNY, compared to 2,341,225,774.83 CNY in the previous year, reflecting a decrease of approximately 27.6%[46]. - The company reported a foreign exchange impact of -11,413,514.64 CNY on cash and cash equivalents, contrasting with a positive impact of 5,674,000.87 CNY in the previous year[46]. Assets and Liabilities - Total assets at the end of the reporting period amount to CNY 30,225,558,790.97, representing a 0.67% increase from the end of the previous year[9]. - Total liabilities amounted to ¥13,380,018,004.07, slightly down from ¥13,473,613,165.12 in the previous period[22]. - Shareholders' equity attributable to the listed company is CNY 10,368,342,116.43, up by 1.73% compared to the previous year[9]. - Total equity attributable to shareholders reached ¥10,368,342,116.43, up from ¥10,191,961,981.05 in the previous period[22]. - Deferred income increased to ¥305,678,087.18 from ¥278,214,493.71, indicating a growth of about 9.9%[22]. Investments and Subsidiaries - The company established a new subsidiary, Chongqing Songshan Membership Hospital Co., Ltd., with a registered capital of CNY 5 million, aiming to integrate medical resources[18]. - The company reported a decrease in trading financial assets by 32.53%, primarily due to the redemption of financial products during the reporting period[14]. - Investment income decreased significantly to ¥10,000,471.18 from ¥95,932,564.71, a decline of 89.58% due to reduced investment income from associated enterprises[34]. - Accounts receivable financing decreased by 30.14%, mainly due to a reduction in notes receivable[14]. - Contract liabilities decreased by 52.24%, attributed to the delivery of goods during the reporting period[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 89,791, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71%[34]. - The top ten shareholders include Tibet Huibang Technology Co., Ltd. (18.71%), Zhang Songshan (5.91%), and Dong Xiaoming (3.58%) among others[34]. Research and Development - Research and development expenses increased to ¥101,564,101.36 from ¥83,364,496.79, marking a growth of approximately 21.8%[22].

Product Development and Innovation - In 2022, the company launched over 10 functional skincare products, enhancing its "big skin" product matrix[4] - The company achieved approval for 1 formulation product and 7 active pharmaceutical ingredients for overseas certification[2] - The company has expanded its product offerings, including the approval of linezolid glucose injection (100ml, 300ml), enhancing its portfolio in skin, tuberculosis, and anti-tumor medications[67] - The company has launched over 10 functional products in the skin care segment, including ceramide essence oil and acne gel, leveraging 30 years of clinical experience in dermatology[67] - The company is focusing on high-value raw materials and key intermediates through collaboration with domestic and international research institutions[145] - The company is actively pursuing new product registrations in the oncology and digestive system medication fields, enhancing its product pipeline[121] - The company aims to develop 3-5 new pharmaceutical products annually and ensure rapid approval of in-progress products[144] - The company is developing new products in the lithium-ion battery electrolyte sector, expanding its downstream industry chain[122] Financial Performance - The company's operating revenue for 2022 was approximately ¥13.23 billion, representing a 6.45% increase compared to ¥12.43 billion in 2021[42] - The net profit attributable to shareholders decreased by 35.12% to approximately ¥433.28 million from ¥670.05 million in the previous year[42] - The net profit after deducting non-recurring gains and losses was approximately ¥408.65 million, down 32.77% from ¥610.11 million in 2021[42] - The net cash flow from operating activities increased by 89.65% to approximately ¥2.41 billion, compared to ¥1.27 billion in 2021[42] - The company reported a total distributable profit of RMB 780,260,536.94 for the reporting period[194] - The company achieved a revenue share of 13.80% from overseas sales in its main business, primarily exporting to large multinational companies such as DuPont and Toray[79] - The company reported a significant asset impairment loss of ¥560.36 million, representing 34.53% of total profit, which is not expected to be sustainable[126] Market Expansion and Strategy - The company aims to strengthen its leading position in the prescription market and expand its market share in the outpatient retail sector[3] - The company is focusing on expanding its market presence in the dermatology sector, which is expected to grow significantly due to increasing health awareness among consumers[54] - The company is actively pursuing market expansion in the OTC sector while strengthening its position in the prescription market[61] - The company has covered over 200,000 terminal points in the outpatient market, actively expanding its marketing channels beyond hospitals[69] - The company has partnered with over 10 online platforms, including Alibaba Health and Meituan, to enhance its e-commerce presence[69] - The company plans to open 20 new chain clinics nationwide, increasing the total to 50 clinics[148] Operational Efficiency and Production Capacity - The company’s raw material drug production bases in Changshou and Hanjing were officially put into operation, enhancing production capacity[7] - The company has established four major formulation production bases and three major raw material production bases, enhancing its supply chain stability and production efficiency[68] - The company invested over 3 billion RMB in production capacity expansion and digital transformation since 2015, significantly increasing production capabilities by 4-8 times at its main production bases[68] - The company is focusing on enhancing production efficiency to improve product competitiveness in the agricultural chemicals sector[57] - The company is committed to smart and green manufacturing to enhance product quality and expand production capacity[77] Research and Development - The company has a strong R&D team and core technologies in the production and purification of chlorosulfonic acid and acyl chloride products, ensuring a competitive edge[80] - The company has established a strong R&D infrastructure with four major centers and nearly 400 R&D personnel, supporting its drug development initiatives[94] - The company has a total of 45 authorized patents in the new materials sector, with 14 being invention patents, showcasing strong R&D capabilities[87] - R&D personnel increased by 8.10% to 1,281 in 2022, with the proportion of R&D staff rising to 10.08% of total employees[122] - The company is focusing on green and clean technology innovations in its production processes to enhance core competitiveness[121] Medical Services and Healthcare - The Beijing Huasheng Rehabilitation Hospital was approved for medical insurance qualifications, becoming a designated medical institution in Beijing[11] - The Chongqing Songshan Hospital served over 1.5 million patients, with the addition of 23 specialty outpatient clinics[10] - The company’s medical services are expected to continue growing, with a focus on innovative healthcare business models[9] - The company has established a comprehensive medical system that enhances collaboration among medical institutions, leveraging advanced technologies from the Swiss Basel Biotherapy Center to improve healthcare quality[98] Sustainability and Environmental Impact - The company has been recognized as a national "green factory" in the pharmaceutical industry, enhancing its sustainability credentials[7] - The company is committed to sustainable development and aims to become a comprehensive provider of agricultural chemical products globally[150] - The company has implemented a circular economy approach by utilizing sulfur dioxide separation and recycling, reducing production costs and environmental impact[103] - The company is addressing environmental policy risks by investing in environmental technology and establishing a risk-oriented internal management system[152] Governance and Compliance - The company adheres to legal and regulatory requirements for corporate governance, ensuring transparency and protection of investor rights[164] - The board of directors consists of 6 members, including 2 independent directors, ensuring compliance with governance standards[165] - The company has established specialized committees, including a strategy committee and an audit committee, to enhance decision-making processes[166] - The internal audit department operates independently and reports to the audit committee, ensuring effective internal control implementation[197] Tourism Business - The company operates three cable cars in the Yulong Snow Mountain Scenic Area and three in the Taibai Mountain National Forest Park, being the sole operator in these areas[83] - The company has a diverse tourism business model that includes cable car transport, scenic area transportation, hotel operations, and tourism performances[83] - The tourism service segment generated revenue of CNY 438,785,148.54, down 14.59% from the previous year[109] - The company faces intensified competition in the tourism market, particularly in the mid-to-high-end hotel sector due to the influx of international hotel brands[159]

公司董事会及管理层衷心感谢广大投资者对公司的关注与支持，欢迎广大投 资者积极参与。 华邦生命健康股份有限公司 董 事 会 证券代码：002004 证券简称：华邦健康 公告编号：2023013 华邦生命健康股份有限公司 关于召开 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在 公司指定信息披露网站巨潮资讯网（www.cninfo.com.cn）披露了公司《2022 年年 度报告》及其摘要。为使广大投资者进一步了解公司经营情况，公司拟于 2023 年 5 月 5 日（星期五）下午 15:00-17:00 在全景网举行 2022 年度业绩说明会，本 次说明会将采用网络远程方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。出席本次年度业绩说明会的人员 有：公司董事、总经理张海安先生，董事、董事会秘书彭云辉女士，独立董事黎 明先生，财务总监王剑先生。 为充分尊重投资者、提 ...